The expression of NK-activating ligands on AML blasts is linked to positive outcomes in AML patients undergoing chemotherapy [24], and genetic knockout of key NK cell receptors increases tumor formation in mice [25]. This evidence concerns the gene KLRD1 and acute myeloid leukemia.